Brief: Enveric Biosciences Reports Positive Results From Animal Studies For EB-373
17/07/2023 14:06
July 17 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES REPORTS POSITIVE RESULTS FROM ANIMAL
STUDIES
DEMONSTRATING ORAL BIOAVAILABILITY AND WELL TOLERATED SIDE
EFFECT PROFILE FOR EB-373
* ENVERIC BIOSCIENCES - ORALLY ADMINISTERED EB-373 RESULTED
IN
DOSE-DEPENDENT INCREASE IN PSILOCIN BLOOD CONCENTRATION IN
PHARMACOKINETIC ANIMAL STUDIES
* ENVERIC BIOSCIENCES - SIDE EFFECT PROFILE WAS WELL
TOLERATED
OVERALL, WITH NOTABLY NO VOMITING & NO SERIOUS ADVERSE EVENTS
OBSERVED AT ANY DOSE LEVEL
Source text for Eikon: ID:nBw377yJQa
Further company coverage: ENVB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003